FIG. 1.

Structures of the cAdVax vectors expressing multiple EBOV antigens. (a) Bivalent cAdVaxE(GPs/z) vaccine expresses single copies each of the SEBOV and ZEBOV GPs; (b) cAdVaxE(GPs) vaccine expresses two copies of the SEBOV GP; and (c) cAdVaxE(GPz) vaccine expresses two copies of the ZEBOV GP. cAdVax-based EBOV vaccine vectors were developed to express multiple EBOV genes for the purpose of developing an effective and safe Ebola virus vaccine. These vectors were based on a replication-defective cAdVax vector platform that differs from other Ad-based vectors in that it contains multiple deletions within the Ad E1, E3, and E4 (except ORF6) genes and multiple insertion sites in the Ad genome (14-16). These deletions allow us to accommodate the insertion of gene sequences up to 7 kb in length. cAdVax vectors were constructed as described previously (14-16). ITR, inverted terminal repeat; hCMVie, human cytomegalovirus intermediate/early promoter; BGH polyA, bovine growth hormone polyadenylation site; Ψ, adenovirus packaging signal.